Advances in Multiple Sclerosis and Experimental Demyelinating Diseases (Current Topics in Microbiology and Immunology, 318)

ISBN 10: 3642437834 ISBN 13: 9783642437830
Verlag: Springer, 2014
Neu Softcover

Verkäufer Ria Christie Collections, Uxbridge, Vereinigtes Königreich Verkäuferbewertung 5 von 5 Sternen 5 Sterne, Erfahren Sie mehr über Verkäufer-Bewertungen

AbeBooks-Verkäufer seit 25. März 2015


Beschreibung

Beschreibung:

In. Bestandsnummer des Verkäufers ria9783642437830_new

Diesen Artikel melden

Inhaltsangabe:

Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people in the United States. With their novel, multifaceted approach to basic science, the authors of this book offer help to clinicians and hope to patients.

Von der hinteren Coverseite:

"There is a need for a paradigm shift in our thinking about the pathogenesis of multiple sclerosis."

Challenging Charcot’s hypothesis that inflammatory response is the primary contributor to demyelination, Dr. Rodriguez and colleagues take a fresh, bold look at the causes and possible treatments of MS.

Assuming oligodendrocyte injury as a prerequisite to MS, the authors explore viruses, toxins and genetic defects as possible culprits. They present novel methods to interrupt and reverse demyelination. This book examines the correlation between axonal loss and clinical deficits, including the implied role of the CD8+ T cell and perforin. It assesses proteases, specifically, kallikrein 6, which are strongly associated with active demyelination. By directing natural autoantibodies against oligodendrocytes that demonstrate remyelination in animal models, the authors envision clinical trials for remyelination enhancement.

As internationally recognized specialists in a wide range of MS disciplines, the authors explore genetic tools for identifying patients who are most likely to experience spontaneous remyelination. Epidemiology studies offer additional avenues of treatment. Examples include uric acid, statin drugs, estrogen and progesterone.

MS affects nearly 400,000 people in the United States, many of whom are between18 and 40 years of age. With their novel, multifaceted approach to basic science—and their applications in understanding cause and treatment—the authors offer help to clinicians and hope to patients.

„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.

Bibliografische Details

Titel: Advances in Multiple Sclerosis and ...
Verlag: Springer
Erscheinungsdatum: 2014
Einband: Softcover
Zustand: New

Beste Suchergebnisse beim ZVAB

Foto des Verkäufers

Moses Rodriguez
Verlag: Springer-Verlag GmbH, 2014
ISBN 10: 3642437834 ISBN 13: 9783642437830
Neu Taschenbuch

Anbieter: preigu, Osnabrück, Deutschland

Verkäuferbewertung 5 von 5 Sternen 5 Sterne, Erfahren Sie mehr über Verkäufer-Bewertungen

Taschenbuch. Zustand: Neu. Advances in Multiple Sclerosis and Experimental Demyelinating Diseases | Moses Rodriguez | Taschenbuch | xiv | Englisch | 2014 | Springer-Verlag GmbH | EAN 9783642437830 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu. Artikel-Nr. 104984180

Verkäufer kontaktieren

Neu kaufen

EUR 141,30
Versand: EUR 70,00
Von Deutschland nach USA

Anzahl: 5 verfügbar

In den Warenkorb

Foto des Verkäufers

Moses Rodriguez
ISBN 10: 3642437834 ISBN 13: 9783642437830
Neu Taschenbuch

Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland

Verkäuferbewertung 5 von 5 Sternen 5 Sterne, Erfahren Sie mehr über Verkäufer-Bewertungen

Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - 'There is a need for a paradigm shift in our thinking about the pathogenesis of multiple sclerosis.'Challenging Charcot's hypothesis that inflammatory response is the primary contributor to demyelination, Dr. Rodriguez and colleagues take a fresh, bold look at the causes and possible treatments of MS.Assuming oligodendrocyte injury as a prerequisite to MS, the authors explore viruses, toxins and genetic defects as possible culprits. They present novel methods to interrupt and reverse demyelination. This book examines the correlation between axonal loss and clinical deficits, including the implied role of the CD8+ T cell and perforin. It assesses proteases, specifically, kallikrein 6, which are strongly associated with active demyelination. By directing natural autoantibodies against oligodendrocytes that demonstrate remyelination in animal models, the authors envision clinical trials for remyelination enhancement. As internationally recognized specialists in a wide range of MS disciplines, the authors explore genetic tools for identifying patients who are most likely to experience spontaneous remyelination. Epidemiology studies offer additional avenues of treatment. Examples include uric acid, statin drugs, estrogen and progesterone.MS affects nearly 400,000 people in the United States, many of whom are between18 and 40 years of age. With their novel, multifaceted approach to basic science-and their applications in understanding cause and treatment-the authors offer help to clinicians and hope to patients. Artikel-Nr. 9783642437830

Verkäufer kontaktieren

Neu kaufen

EUR 160,49
Versand: EUR 62,88
Von Deutschland nach USA

Anzahl: 1 verfügbar

In den Warenkorb